Summary
ATLAS is a powerful in silico drug discovery platform leveraging the latest advances in high-performance and quantum computing. The platform is the result of decades of research by leading experts in molecular dynamics. The technology is grounded on over 100 peer-reviewed papers and two ERC grants. Our beta code has gathered important accolades like the prestigious ATOS-Joseph Fourier prize and first place at the foremost rational drug design competition—the SAMPL challenge.
ATLAS can replace costly and laborious experiments. It can even run entire drug discovery campaigns in silico, reducing cycle times and cost by at least 50%. By 2027, we will have a 35-project portfolio, and the first ATLAS-generated compound will reach the clinic. Thereafter, our objective is to generate a new candidate every 18 months. That year, our team will surpass 50 people and we’ll expand into the US market. We aim at securing a leadership position in the nascent in-silico drug discovery market.
ATLAS can replace costly and laborious experiments. It can even run entire drug discovery campaigns in silico, reducing cycle times and cost by at least 50%. By 2027, we will have a 35-project portfolio, and the first ATLAS-generated compound will reach the clinic. Thereafter, our objective is to generate a new candidate every 18 months. That year, our team will surpass 50 people and we’ll expand into the US market. We aim at securing a leadership position in the nascent in-silico drug discovery market.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190141418 |
| Start date: | 01-09-2022 |
| End date: | 31-08-2024 |
| Total budget - Public funding: | 4 249 375,00 Euro - 2 500 000,00 Euro |
Cordis data
Original description
ATLAS is a powerful in silico drug discovery platform leveraging the latest advances in high-performance and quantum computing. The platform is the result of decades of research by leading experts in molecular dynamics. The technology is grounded on over 100 peer-reviewed papers and two ERC grants. Our beta code has gathered important accolades like the prestigious ATOS-Joseph Fourier prize and first place at the foremost rational drug design competition—the SAMPL challenge.ATLAS can replace costly and laborious experiments. It can even run entire drug discovery campaigns in silico, reducing cycle times and cost by at least 50%. By 2027, we will have a 35-project portfolio, and the first ATLAS-generated compound will reach the clinic. Thereafter, our objective is to generate a new candidate every 18 months. That year, our team will surpass 50 people and we’ll expand into the US market. We aim at securing a leadership position in the nascent in-silico drug discovery market.
Status
SIGNEDCall topic
HORIZON-EIC-2021-ACCELERATORCHALLENGES-01-01Update Date
09-02-2023
Images
No images available.
Geographical location(s)
Structured mapping
